AIM Immunotech vs Inmune Bio
AIM Immunotech is the larger business, with $88,000 of revenue in fiscal 2025 against $50,000 for Inmune Bio (1.8 times as much). Inmune Bio grew faster (257.1% against -48.2%). AIM Immunotech kept more of each dollar of sales as profit: a net margin of -15861.4% against -91866.0%.
| Latest fiscal year | AIM ImmunotechAIM, 2025 | Inmune BioINMB, 2025 |
|---|---|---|
| Revenue | $88,000 | $50,000 |
| Revenue growth | -48.2% | 257.1% |
| Net income | −$14.0m | −$45.9m |
| Operating margin | -13254.5% | -94766.0% |
| Net margin | -15861.4% | -91866.0% |
| Return on equity | — | -165.2% |
| Free cash flow | −$11.0m | −$23.6m |
| Cash | $3.0m | $24.8m |
| Total debt | $8.0m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 19 | — |
| Market value | $4.7m | $36.2m |
| Price vs our value range | — | — |
| Moat score | 5 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 6 buys, 0 sales | 0 buys, 0 sales |